Meagan Cobb
Family Medicine · Hinton, WVNPI 1871937102
Payments from drug & device makers
Across 99 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$484
- Amgen$164
- Novartis$161
- Lilly USA, LLC$148
- Genentech USA, Inc.$145
- Novo Nordisk$129
- plus $521 from 16 others
What the payments were for
- Food & beverage$1,751100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 29 | $484 |
| Amgen(2 entities) | 10 | $164 |
| Novartis | 9 | $161 |
| Lilly USA, LLC | 8 | $148 |
| Genentech USA, Inc. | 5 | $145 |
| Novo Nordisk | 8 | $129 |
| Merck | 7 | $109 |
| Abbott | 3 | $69 |
| Boehringer Ingelheim | 4 | $68 |
| Exact Sciences | 3 | $60 |
| Alkermes, Inc. | 1 | $29 |
| Amarin Pharma, Inc. | 2 | $26 |
| Biogen | 1 | $23 |
| Scilex Pharmaceuticals Inc. | 1 | $19 |
| Bioventus LLC | 1 | $17 |
| GSK | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Organogenesis Inc. | 1 | $14 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Pfizer | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
How this compares
$1,751 in reported general payments places this provider in the 75th percentile of 843 family medicine providers in West Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 22 | $40,160 |
| MounjaroTirzepatide | 26 | $26,811 |
| FarxigaDapagliflozin Propanediol | 24 | $23,164 |
| TrulicityDulaglutide | 20 | $20,680 |
| EliquisApixaban | 16 | $18,279 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $13,410 |
| Repatha SureclickEvolocumab | 20 | $10,763 |
| Spiriva RespimatTiotropium Bromide | 16 | $7,959 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 55 | $1,757 |
| Epinephrine | 11 | $1,314 |
| SynthroidLevothyroxine Sodium | 12 | $1,178 |
| Atorvastatin Calcium | 107 | $716 |
| Metformin Hcl ErMetformin Hcl | 45 | $678 |
| Omeprazole | 65 | $656 |
| Famotidine | 38 | $632 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $148 | $47,49146 claims |
| Novo NordiskOzempic | $129 | $40,16022 claims |
| AstraZenecaFarxiga | $16 | $23,16424 claims |
| PfizerEliquis | $13 | $18,27916 claims |
| GSKTrelegy Ellipta | $16 | $13,41013 claims |
| Boehringer IngelheimSpiriva Respimat | $68 | $7,95916 claims |
| AbbVieSynthroid | $484 | $1,17812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 843 family medicine providers in West Virginia.
Other family medicine in Hinton
- Wilbur SineMorgantown$179K
- Dorian WilliamsMorgantown$169K
- Julie DetempleSouth Charleston$129K
- Clemente DiazRichwood$127K
- John CornellHuntington$94K
- Mark CucuzzellaHarpers Ferry$59K
- Courtney PilkertonMorgantown$45K
- Isha WoofterClarksburg$27K
- Dominick WoofterClarksburg$27K
- Ryan RunyonPrinceton$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.